Novo Nordisk Ozempic Receives EU Approval for Type 2 Diabetes
EU Regulatory Clearance and Commercialization Foundation
The European Commission (EC) approved Novo Nordisk (NVO)'s Ozempic (active ingredient: semaglutide) for the treatment of adult patients with type 2 diabetes on February 8, 2018. This final marketing authorization followed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on November 9, 2017. Ozempic can be used as monotherapy or in combination with other diabetes therapies for patients for whom metformin use is inappropriate, in addition to diet and exercise. Following FDA approval in December 2017, the EU approval for the 28 member states significantly reduced the commercialization risks for semaglutide on a global scale.
Weekly Treatment Targeting the GLP-1 Receptor
Ozempic is a once-weekly subcutaneous injection that activates the human glucagon-like peptide-1 receptor (GLP-1R), enhancing glucose-dependent insulin secretion while reducing glucagon secretion and appetite. The approval was based on the SUSTAIN program, which included eight Phase 3a trials involving more than 8,000 adult patients. The results showed a consistent reduction in HbA1c and weight compared to comparator therapies, as reflected in the product label. Compared to earlier GLP-1 therapies requiring daily dosing, Ozempic offers improved convenience, enhancing medication adherence and prescription expansion in the management of chronic diseases.
Balance of Cardiovascular Efficacy and Safety
In the Phase 3 trial SUSTAIN 6, which included 3,297 patients at high cardiovascular risk, semaglutide reduced the composite risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 26% compared to placebo, with a hazard ratio (HR) of 0.74 and a 95% confidence interval of 0.58–0.95. These results provided clinical differentiation in the type 2 diabetes market, where both blood glucose control and cardiovascular risk management are required. However, signals of gastrointestinal adverse reactions and increased risk of diabetic retinopathy were observed. While EMA concluded that the benefits outweigh the risks, it requested further investigation into retinopathy and post-marketing surveillance.
Competitive Landscape and Market Potential
At the time of approval, key competitors included Eli Lilly (LLY)'s Trulicity (dulaglutide, a GLP-1R agonist), AstraZeneca (AZN)'s Bydureon (exenatide, a GLP-1R agonist), and Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin, an SGLT2 inhibitor). Later, Eli Lilly's Mounjaro (tirzepatide, a dual GIP-GLP-1 receptor agonist) received approval in the U.S. and EU in 2022, intensifying efficacy-based competition. Despite this, Ozempic achieved sales of 127.089 billion Danish kroner in 2025, growing into the world's largest diabetes therapy asset. The EU approval proved to be a key regulatory milestone in forming a blockbuster product.
The EC's approval on February 8, 2018, enabled the sale of Ozempic across the EU, accelerating Novo Nordisk's expansion of its GLP-1 franchise. The 26% reduction in major cardiovascular event risk from SUSTAIN 6 strengthened Ozempic's prescribing competitiveness against Trulicity and Bydureon, although the retinopathy signal remains a safety variable requiring ongoing monitoring by researchers and clinicians. Ozempic's 2025 sales reached 127.089 billion Danish kroner, demonstrating the long-term value of EU approval in transforming a clinical asset into a global blockbuster. The mid-to-long-term competitive focus will center on the differentiation between Mounjaro's dual GIP-GLP-1 receptor agonism and the expansion of semaglutide's cardiovascular, renal, and peripheral arterial disease evidence base.
Source: EMA (ema)